Home Research Grants Chemodenervation Grant Winners

Chemodenervation Grant Winners

Funded by the Allergan Foundation

2021

Kelly Ieong, Stony Brook University Hospital
Incidence and impact of antibodies against OnabotulinumtoxinA (Botox) on treatment efficacy in patients with idiopathic overactive bladder (OAB): a pilot study

2020

Megan Bradley, MD, University of Pittsburgh
Whole-Exome Sequencing in Women with Refractory Overactive Bladder: Biomarker Prediction of Treatment Response

2019

Hatim Thaker, MD, Boston Children's Hospital/Harvard Medical School
In Vivo Efficacy of Botulinum Neurotoxins on a Novel Preclinical Mouse Model

2019

Whitney K. Hendrickson, MD, Duke University Health System
Model for Predicting Efficacy of Treatment and Complications in Women after Intradetrusor OnabotulinumtoxinA for NonNeurogenic Urgency Incontinence

2018

Esther Han, DO, Beaumont Health, Michigan
Is Less More? Does Decreasing OnabotulinumtoxinA Injection Sites in the Bladder Increase Patient Satisfaction While Maintaining Efficacy?

2018

Temitope Rude, MD, University of Southern California, Los Angeles, CA
Access to OnabotulinumtoxinA Treatment in Neurogenic Detrusor Overactivity

2018

R. Trafford Crump, PhD, University of Calgary, Calgary, Alberta, Canada
The Use of Chemodenervation to Treat Overactive Bladder in Elderly Patients

2018

Unwanaobong Nseyo, MD, MHS, UC San Diego, San Diego, CA
Multicenter, Prospective Evaluation of Intradetrusor Injections of Botulinum Toxin-A in an Adult Myelomeningocele Population

2017

Rachel Sosland, MD, Vanderbilt University Medical Center, Nashville, TN
Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection: A Non-Inferiority Trial

2017

Raveen Syan, MD, Stanford University, Stanford, CA
Feasibility and Efficacy of Transvaginal OnabotulinumtoxinA Chemodenervation of the Trigone for the Third Line Treatment of Refractory Overactive Bladder

2016

Yingchun Zhang, PhD, University of Houston, Houston, TX
QUANTITATIVE MAPPING OF THE HYPERTONICITY OF THE PELVIC FLOOR MUSCLES USING HIGH-DENSITY SURFACE EMG

2016

Jessica C. Lloyd, MD, Cleveland Clinic, Cleveland, OH
A PROSPECTIVE COHORT TRIAL OF PELVIC FLOOR CHEMODENERVATION IN PATIENTS UNDERGOING PHYSICAL THERAPY FOR HIGH TONE PELVIC FLOOR DYSFUNCTION

2016

A. Lenore Ackerman, MD, PhD, Cedars-Sinai Medical Center, Beverly Hills, CA
THE MICROBIOME AS A PREDICTOR OF OUTCOMES OF INTRAVESICAL BOTULINUM TOXIN INJECTION

2015

Amy Dobberfuhl, Stanford University School of Medicine
LOCALIZATION OF ONABOTULINUMTOXINA AND CYSTOMETRIC RESPONSE FOLLOWING SINGLE VERSUS MULTIPLE INJECTIONS FOR THE TREATMENT OF OVERACTIVE BLADDER IN A RAT MODEL

2015

Rose Khavari, Houston Methodist Hospital
EVALUATION OF CENTRAL INHIBITORY EFFECTS OF INTRAVESICAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH NEUROGENIC AND NON-NEUROGENIC DETRUSOR OVERACTIVITY

2015

Paholo Barboglio Romo, University of Michigan
ONABOTULINUM TOXIN REPEATED INJECTIONS IN CERVICAL SPINAL CORD INJURY

2014

Brooke Brown, Fellow, Vanderbilt University
EFFECTS OF BLADDER ONABOTULINUM TOXIN INJECTION ON CENTRAL SENSITIZATION IN OAB PATIENTS.

2014

Andrea Russo, Fellow, Yale University
CHEMODENERVATION WITH ONABOTULINUMTOXINA AND ITS EFFECT ON BLADDER UROTHELIAL FUNCTION

2014

Eliza Lamin, Resident; Lisa Parrillo, Resident, University of Pennsylvania
COMPARISON OF THE TREATMENT OF REFRACTORY BLADDER PAIN SYNDROME WITH DIMETHYL SULFOXIDE (DMSO) ALONE AND DMSO AS A CARRIER FOR BOTULINUM TOXIN A INSTILLATION